Schultz K R, Bader S, Nelson D, Wang M D, HayGlass K T
Department of Pediatrics, University of British Columbia and British Columbia's Children's Hospital, Vancouver, Canada.
Transplantation. 1997 Oct 15;64(7):1055-65. doi: 10.1097/00007890-199710150-00019.
Using murine models, we have shown that the lysosomotropic amine, chloroquine, is effective in the prevention of graft-versus-host disease (GVHD) mediated by donor T cells reactive with recipient minor histocompatibility antigens (MiHCs). Because lysosomotropic amines can suppress major histocompatibility complex (MHC) class II antigen presentation, their mechanism of action is potentially different from current immune suppressant drugs used to control GVHD such as cyclosporine.
We investigated the use of cyclosporine and the lysosomotropic amines chloroquine and hydroxychloroquine in combination for additive or synergistic immunosuppression on T-cell responses in vitro to MiHC and MHC in mice.
We found that similar concentrations of chloroquine and hydroxychloroquine suppress the T-cell response to MiHC in mice (C57BL/6 anti-BALB.B) and that lysosomotropic amines in combination with cyclosporine result in synergistic suppression of a proliferative response to MiHC. Similar suppression and synergy appear to be present in an alloreactive response (C57BL/6 anti-BALB/c). Direct inhibition by chloroquine of T-cell proliferative responses induced by anti-CD3epsilon in the absence of antigen-presenting cells is present at higher concentrations than that required to suppress responses to MiHC or MHC. Chloroquine appears to induce decreased T-cell viability at high concentrations. This effect does not appear to be due to decreased T-cell production of interleukin-2 or interferon-gamma. At lower concentrations (<25 microg/ml), chloroquine can also decrease the ability of antigen-presenting cells to stimulate an a C57BL/6 anti-BALB/c T-cell response and can inhibit MHC class II expression after activation with lipopolysaccharide.
Lysosomotropic amines in combination with cyclosporine appear to be synergistic in the suppression of T-cell proliferation to MiHC and MHC. Use of chloroquine in combination with cyclosporine may result in improved control of GVHD.
我们利用小鼠模型表明,溶酶体促旋胺氯喹在预防由与受体次要组织相容性抗原(MiHC)反应的供体T细胞介导的移植物抗宿主病(GVHD)方面是有效的。由于溶酶体促旋胺可以抑制主要组织相容性复合体(MHC)II类抗原呈递,其作用机制可能与目前用于控制GVHD的免疫抑制药物如环孢素不同。
我们研究了环孢素与溶酶体促旋胺氯喹和羟氯喹联合使用对小鼠体外T细胞对MiHC和MHC反应的相加或协同免疫抑制作用。
我们发现,相似浓度的氯喹和羟氯喹可抑制小鼠(C57BL/6抗BALB.B)对MiHC的T细胞反应,且溶酶体促旋胺与环孢素联合使用可协同抑制对MiHC的增殖反应。在同种异体反应(C57BL/6抗BALB/c)中似乎也存在相似的抑制和协同作用。在没有抗原呈递细胞的情况下,氯喹对由抗CD3ε诱导的T细胞增殖反应的直接抑制作用所需浓度高于抑制对MiHC或MHC反应所需的浓度。氯喹在高浓度时似乎会导致T细胞活力下降。这种作用似乎不是由于T细胞白细胞介素-2或干扰素-γ产生减少所致。在较低浓度(<25μg/ml)时,氯喹还可降低抗原呈递细胞刺激C57BL/6抗BALB/c T细胞反应的能力,并可抑制脂多糖激活后MHC II类分子的表达。
溶酶体促旋胺与环孢素联合使用似乎在抑制T细胞对MiHC和MHC的增殖方面具有协同作用。氯喹与环孢素联合使用可能会改善对GVHD的控制。